Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

er of 2012.

Operating ExpensesResearch and development expenses in 2012 were $19.5 million, compared to $21.2 million in 2011.  Research and development expenses decreased primarily as a result of a reduction in the Company's indirect operating expenses and direct costs for the Valortim® program, partially offset by higher direct SparVax® program expenses.

Expenses associated with general and administrative functions decreased to $11.6 million from $14.3 million for the years ended December 31, 2012 and 2011, respectively. The decrease in general and administrative expense in 2012 was primarily the result of a reduction in legal and other general and administrative expenses, partially offset by a one-time insurance recovery.

Net LossFor the year ended December 31, 2012, PharmAthene's net loss was $4.9 million, or $0.10 per share, compared to a net loss of $3.8 million, or $0.08 per share, for the year ended December 31, 2011. The increase in net loss primarily consists of a reduction in other income/expenses of $6.4 million associated with the change in the fair value of the Company's derivative instruments, offset by a decrease in operating expenses of $4.5 million.

Cash and Accounts ReceivableAs of December 31, 2012, the Company had cash and cash equivalents, restricted cash, and U.S. government accounts receivable and unbilled accounts receivable totaling approximately $19.2 million, compared to $18.8 million as of December 31, 2011. The year-over-year difference was primarily a result of cash used in operations, offset by funding provided under a term loan and revolving line of credit with GE Capital, which was completed in the first quarter of 2012.

Conference Call and Webcast InformationPharmAthene management will be hosting a conference call to discuss the Company's year-end 2012 financial and operational results. The call is scheduled to begin at 4:30 pm Eastern Time on Wednesday,
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... (PRWEB) May 17, 2013 RURO ... ezColony version 4.1, a versatile refinement to the ... software solution, improves its advanced methodical management for ... with ezColony 4.1. The network-based platform provides user ... effective research. While continuing to emphasize streamlined tasks, ...
(Date:5/16/2013)... 2013 ISPE announced ... CAE, to the newly created position of Vice ... Myers will be responsible for stimulating ISPE’s revenue ... advancing the Society’s Member-led and staff-driven business model, ... refine organizational, membership and product marketing. , “Barbara ...
(Date:5/16/2013)... May 16, 2013 Kitware ... solutions, today announces new Phase II SBIR funding ... continued development of an open-source, high performance computing ... integration framework enables researchers to select only the ... of simulation, computation, or analysis tasks. , ...
(Date:5/16/2013)... On average, developing a new drug takes ... Despite this investment, less than 10% of drugs make ... clinical trial design optimally structured to balance time, cost ... Frederic Sax, Global Head of the Center for Drug ... information and technology in upfront clinical trial planning and ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... SANTA MONICA, Calif. and LAS VEGAS, Aug. 11 Cord ... umbilical cord blood stem cell preservation companies ( http://www.cordblood-america.com ... of stem cells to families nationwide and internationally, announced today that ... Las Vegas for conversion into a state-of-the-art laboratory for the storage ...
... ... Center for Orthopedics in Sheffield Village, Ohio, now offers OtisKnee® Custom Fit Knee Replacement. ... fit and alignment -- and a faster return to an active lifestyle. , ... Sheffield Village, Ohio (PRWEB) ...
... , FRAZER, Pa., Aug. 10 ... has completed its previously announced acquisition of all of the outstanding ... a result of the acquisition, Arana is now a wholly-owned subsidiary ... Frank Baldino Jr., Ph.D., said, "We are excited about the advanced ...
Cached Biology Technology:Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 2Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009 3William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 2William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 3William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement 4Cephalon Completes Acquisition of Arana Therapeutics 2Cephalon Completes Acquisition of Arana Therapeutics 3
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
(Date:5/16/2013)... from Canada and around the world are meeting ... Neuroscience Meeting will showcase the latest in research ... reveal clues to understanding the disorders that affect ... and this meeting will showcase the best of ... says Sam David, President of the Canadian Association ...
(Date:5/16/2013)... Germany , May 16, 2013 ... Value Enhancement Award on Tuesday to Germany,s ... its exceptional biometric border control system. DERMALOG ... with the Best Practices Award in the category Global ... its cutting edge Biometric   Border Control System ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometrics and Border Control Award for DERMALOG 2Global Biometrics and Border Control Award for DERMALOG 3Global Biometrics and Border Control Award for DERMALOG 4
... AWRE ), a leading supplier of broadband technology and ... June 30, 2011.   Revenue for the second quarter ... $5.0 million in the same quarter last year. The net loss ... diluted share. These results compared to a net loss of $148,000, ...
... 1, 2011 /PRNewswire-Asia/ -- Clearbridge Accelerator announced today that ... well-established venture capitalist based in the Silicon Valley. Mr ... of Draper Fisher Jurvetson (DFJ), is well known for ... Clearbridge Accelerator is a technology incubator ...
... -- A visiting researcher from Sweden in the Indiana University ... international team in culturing, characterizing and formally naming a new ... DNA sequencing from environmental samples. ,Structures on Roots ... known as Soil Clone Group 1 (SCG1), has now been ...
Cached Biology News:Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3